VanEck Bionic Engineering UCITS ETF Acc
| Issuer: Van Eck |
| Asset Class: Equity |
| TER: 55bps |
| Trading Currency: GBP |
| Pays Income: False |
| Listing Date: 07 Dec 2022 |
| Ticker: CYBG |
| ISIN: IE0005TF96I9 |
This fund provides targeted exposure to the transformative intersection of healthcare and advanced technology, focusing on companies driving innovation in medical robotics, bionics, and specialized instrumentation. The investment thesis is built upon powerful, long-term secular trends, including aging global populations demanding better healthcare, the continuous push for more effective and less invasive medical procedures, and technological advancements that are revolutionizing patient care. As healthcare systems globally seek greater efficiency and improved outcomes, the demand for sophisticated medical devices and digital health solutions is expected to experience sustained growth, positioning this sector at the forefront of modern medicine.
The portfolio is composed of global companies that are leaders in their respective niches. This includes firms developing state-of-the-art surgical robotics that enhance precision and reduce recovery times, companies creating advanced diagnostic imaging equipment for earlier disease detection, and innovators in the field of bionics and prosthetics that dramatically improve quality of life. Other key areas of investment include specialized medical instruments, 3D printing of medical components, and advanced healthcare tracking systems. By investing in these pure-play companies, the fund captures the growth potential of a highly specialized and innovative segment of the healthcare industry, moving beyond traditional pharmaceuticals and biotech.
This thematic investment offers a way to participate in a structural growth story that is reshaping the future of healthcare. The constituent companies often possess strong intellectual property and significant barriers to entry, benefiting from continuous research and development efforts. For investors looking to diversify their portfolios with exposure to a high-growth, technology-driven theme, this strategy offers a compelling opportunity to invest in the firms that are not just treating diseases, but fundamentally changing how medical care is delivered worldwide.
